Raymond James Financial’s IGC Pharma IGC Stock Holding History

Raymond James Financial’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-178	Closed	-$55	–	5789
2025 Q2	$55	Buy	+178	New	+$53	﹤0.01%	6880

Other funds holding IGC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's IGC Position: Q3 2025 in Review

Raymond James Financial sold out of IGC Pharma (IGC) in Q3 2025, closing a stake of 178 shares — an estimated $55 sold.

Raymond James Financial first reported a position in IGC in Q2 2025 and held it in 1 quarter. The position peaked at $55 in Q2 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q3 2025.

Raymond James Financial reported no remaining IGC Pharma position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 178 IGC Pharma shares in Q3 2025, an estimated $55.
Raymond James Financial first reported a position in IGC Pharma in Q2 2025 and held it in 1 quarter.
Raymond James Financial's IGC Pharma position peaked at $55 in Q2 2025.
35 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.